<code id='CEC99BFAED'></code><style id='CEC99BFAED'></style>
    • <acronym id='CEC99BFAED'></acronym>
      <center id='CEC99BFAED'><center id='CEC99BFAED'><tfoot id='CEC99BFAED'></tfoot></center><abbr id='CEC99BFAED'><dir id='CEC99BFAED'><tfoot id='CEC99BFAED'></tfoot><noframes id='CEC99BFAED'>

    • <optgroup id='CEC99BFAED'><strike id='CEC99BFAED'><sup id='CEC99BFAED'></sup></strike><code id='CEC99BFAED'></code></optgroup>
        1. <b id='CEC99BFAED'><label id='CEC99BFAED'><select id='CEC99BFAED'><dt id='CEC99BFAED'><span id='CEC99BFAED'></span></dt></select></label></b><u id='CEC99BFAED'></u>
          <i id='CEC99BFAED'><strike id='CEC99BFAED'><tt id='CEC99BFAED'><pre id='CEC99BFAED'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:9356
          RFK Jr. for first opinion
          STAT, AP

          Robert F. Kennedy Jr. said Tuesday that he will head up a panel on vaccine safety for Donald Trump.

          The president-elect’s transition team spokeswoman later walked that back, saying that he is “exploring the possibility” of forming a panel on autism, but “no decisions have been made.”

          advertisement

          Let’s hope Trump drops any idea of a vaccine panel headed by Kennedy. For more than a decade, Kennedy has promoted anti-vaccine propaganda completely unconnected to reality. If Kennedy’s panel leads to even a small decline in vaccine rates across the country, it will result in the waste of untold amounts of money and, in all likelihood, the preventable deaths of infants too young to be vaccinated.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more

          KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          Readout Newsletter: The latest at Gilead, Catalent, and the NIH

          Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb